Compare MDRR & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDRR | PASG |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 19.2M |
| IPO Year | N/A | 2020 |
| Metric | MDRR | PASG |
|---|---|---|
| Price | $11.36 | $5.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 1.5K | ★ 32.8K |
| Earning Date | 03-02-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.47 | $0.35 |
| 52 Week High | $14.52 | $20.00 |
| Indicator | MDRR | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 48.05 |
| Support Level | $11.26 | $4.97 |
| Resistance Level | $12.20 | $5.90 |
| Average True Range (ATR) | 0.44 | 0.43 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 73.36 | 56.09 |
Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.